Association Between Insertion-Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Treatment Response to Antipsychotic Medications: A Study of Antipsychotic-Naïve First-Episode Psychosis Patients and Nonadherent Chronic Psychosis...

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 27

PMID 36293037

Authors

Sergej Nadalin

Sanja Devic Pavlic

Vjekoslav Peitl

Dalibor Karlovic

Lena Zatkovic

Smiljana Ristic

Alena Buretic-Tomljanovic

Hrvoje Jakovac

Affiliations

Soon will be listed here.

Abstract

We investigated whether a functional insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme (ACE) influenced antipsychotic treatment. At baseline, and after 8 weeks of treatment with various antipsychotic medications, we assessed patients’ Positive and Negative Syndrome Scale (PANSS) scores, PANSS factors, and metabolic-syndrome-related parameters (fasting plasma lipid and glucose levels, and body mass index). A total of 186 antipsychotic-naïve first-episode psychosis patients or nonadherent chronic psychosis individuals (99 males and 87 females) were genotyped by polymerase chain reaction analysis. The ACE-I/D polymorphism was significantly associated with changes in PANSS psychopathology only (p < 0.05). Compared to ACE-II homozygous males, ACE-DD homozygous and ACE-ID heterozygous males manifested significantly greater decreases in PANSS positive score, PANSS excitement factor, and PANSS cognitive factor. ACE-DD homozygous females manifested higher decreases in PANSS depression factor compared to ACE-II homozygous and ACE-ID heterozygous females. The polymorphism’s effect size was estimated as moderate to strong, while its contribution to the PANSS psychopathology ranged from ~5.4 to 8.7%, with the lowest contribution observed for PANSS positive score changes and the highest for PANSS depressive factor changes. Our results indicate that ACE-I/D polymorphism had a statistically significant but weak gender-specific impact on psychopathology data, and showed no association between ACE-I/D polymorphism and metabolic-syndrome-related parameters.

References

Niu W, Qi Y, Gao P, Zhu D . Angiotensin converting enzyme D allele is associated with an increased risk of type 2 diabetes: evidence from a meta-analysis. Endocr J. 2010; 57(5):431-8. DOI: 10.1507/endocrj.k09e-360. View

Barth C, Villringer A, Sacher J . Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015; 9:37. PMC: 4335177. DOI: 10.3389/fnins.2015.00037. View

Shanmugam V, Sell K, Saha B . Mistyping ACE heterozygotes. PCR Methods Appl. 1993; 3(2):120-1. DOI: 10.1101/gr.3.2.120. View

Sanada M, Higashi Y, Nakagawa K, Sasaki S, Kodama I, Tsuda M . Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol. 2001; 37(6):1529-35. DOI: 10.1016/s0735-1097(01)01191-3. View

Fawaz C, Martel P, Leo D, Trudeau L . Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. BMC Neurosci. 2009; 10:96. PMC: 2745416. DOI: 10.1186/1471-2202-10-96. View

Ristic S, Lovrecic L, Starcevic-cizmarevic N, Brajenovic-Milic B, Sega Jazbec S, Barac-Latas V . No association of CCR5delta32 gene mutation with multiple sclerosis in Croatian and Slovenian patients. Mult Scler. 2006; 12(3):360-2. DOI: 10.1191/135248506ms1305sr. View

Wincewicz D, Braszko J . Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders. Pharmacopsychiatry. 2017; 50(6):233-247. DOI: 10.1055/s-0043-112345. View

Hui L, Wu J, Zhang X, Lv J, DU W, Kou C . Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and first-episode patients with schizophrenia in a Chinese Han population. Hum Psychopharmacol. 2014; 29(3):274-9. DOI: 10.1002/hup.2396. View

van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B . The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res. 2006; 85(1-3):280-7. DOI: 10.1016/j.schres.2006.03.021. View

10.

Nagamine T . Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics. Neuropsychiatr Dis Treat. 2008; 4(1):289-94. PMC: 2515891. DOI: 10.2147/ndt.s2367. View

11.

Bergovec M, Reiner Z, Milicic D, Vrazic H . Differences in risk factors for coronary heart disease in patients from continental and Mediterranean regions of Croatia. Wien Klin Wochenschr. 2009; 120(21-22):684-92. DOI: 10.1007/s00508-008-1065-7. View

12.

Gadelha A, Yonamine C, Ota V, Oliveira V, Sato J, Belangero S . ACE I/D genotype-related increase in ACE plasma activity is a better predictor for schizophrenia diagnosis than the genotype alone. Schizophr Res. 2015; 164(1-3):109-14. DOI: 10.1016/j.schres.2015.01.044. View

13.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F . An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4):1343-6. PMC: 296868. DOI: 10.1172/JCI114844. View

14.

Wallwork R, Fortgang R, Hashimoto R, Weinberger D, Dickinson D . Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012; 137(1-3):246-50. PMC: 3351536. DOI: 10.1016/j.schres.2012.01.031. View

15.

Jacobs E, DEsposito M . Estrogen shapes dopamine-dependent cognitive processes: implications for women's health. J Neurosci. 2011; 31(14):5286-93. PMC: 3089976. DOI: 10.1523/JNEUROSCI.6394-10.2011. View

16.

Nani J, Dal Mas C, Yonamine C, Ota V, Noto C, Belangero S . A study in first-episode psychosis patients: does angiotensin I-converting enzyme (ACE) activity associated with genotype predict symptoms severity reductions after treatment with the atypical antipsychotic risperidone?. Int J Neuropsychopharmacol. 2020; . PMC: 7745254. DOI: 10.1093/ijnp/pyaa050. View

17.

Song G, Lee Y . The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson's disease: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2014; 16(2):434-42. DOI: 10.1177/1470320313495909. View

18.

Herrera-Estrella M, Apiquian R, Fresan A, Sanchez-Torres I . The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. BMC Psychiatry. 2005; 5:22. PMC: 1090597. DOI: 10.1186/1471-244X-5-22. View

19.

Servonnet A, Minogianis E, Bouchard C, Bedard A, Levesque D, Rompre P . Neurotensin in the nucleus accumbens reverses dopamine supersensitivity evoked by antipsychotic treatment. Neuropharmacology. 2017; 123:10-21. DOI: 10.1016/j.neuropharm.2017.05.015. View

20.

Trieu B, Remmers B, Toddes C, Brandner D, Lefevre E, Kocharian A . Angiotensin-converting enzyme gates brain circuit-specific plasticity via an endogenous opioid. Science. 2022; 375(6585):1177-1182. PMC: 9233526. DOI: 10.1126/science.abl5130. View